ARHGEF2 and hepatocellular carcinoma: Notwithstanding, this study provided a new insight into the potential mechanism of drug resistance related to ER stress, emphasizing that ARHGEF2/EDN1 is a potential antiangiogenic therapeutic target in HCC.